ALNY vs INTS · P/E 76, rev $2.25B vs $7.7M cap
Alnylam Pharmaceuticals Inc (ALNY) versus Intensity Therapeutics, Inc. Common stock (INTS) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Latest reported ALNY revenue for 2024-12-31 was $2.25B. Net income was -$278.2M. Revenue was up 23.0% from 2023-12-31 to 2024-12-31. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
INTS does not have a complete income-statement cache yet.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. INTS currently screens at market cap $7.7M.
Not investment advice. Open the ALNY and INTS stock pages for the full models.
Not investment advice.